Companies › BnH Research
1 active drug program in 1 registered trial: 1 Phase 1; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BnH-015B GluN2B-selective NMDA receptor positive allosteric modulator; regulates BDNF/TRKβ and micr | GRIN2B, BDNF, NTRK2 | Phase 1 | Alzheimer Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06535308 | BnH-015B | Phase 1 | Alzheimer Disease | Neurology | Apr 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.